KRAS and pancreatic neoplasm: Moreover, prior research[53] has demonstrated that AHNAK2 not only promotes the proliferation and confers drug resistance to pancreatic cancer cells via the activation of the KRAS/p53 pathway but also notably influences and cell-extracellular matrix adhesion.